Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren extension in nonsense mutation aniridia
NCT04117880Phase 2Withdrawn
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Dec 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ataluren in aniridia, sponsored by PTC Therapeutics, Inc. Primary endpoint: Treatment-Emergent Adverse Events at 104 weeks. Planned start Dec 2018; status: withdrawn.
02
Drugs
ataluren
03
Conditions
aniridia
Beyond the preview
Go deeper on NCT04117880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04117880.